Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide: A preclinical study

Pharmacological Reports

Volumn 58, Issue 3, 2006, Pages 431-434

  Świader, Mariusz J ^a   Łuszczki, Jarogniew J ^a   Paruszewski, Ryszard ^b   Czuczwar, Stanisław J ^a,c   Turski, Waldemar A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Chimney test; Maximal electroshock; Nicotinic acid benzylamide; Protective index

Indexed keywords

ANTICONVULSIVE AGENT; NICOTINIC ACID BENZYLAMIDE; NICOTINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; COORDINATION DISORDER; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRIC SHOCK; EPILEPSY; MOTOR COORDINATION; MOUSE; NEUROTOXICITY; NONHUMAN;

EID: 33746356234     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Boissier JR, Tardy J, Diverres JC: Une nouvelle methode simple pour explorer l'action "tranquilisante": le test de la cheminee. Med Exp, 1960, 3, 81-84.
2. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ: The non-competitive AMPA/ kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol, 1995, 281, 319-326.
3. Czuczwar SJ, Meldrum B: Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur J Pharmacol, 1982, 83, 335-338.
4. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
5. Löscher W, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res, 1991, 9, 1-10.
6. Löscher W, Fassbender CP, Nölting; B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res, 1991, 8, 79-94.
7. Paruszewski R, Rostafińska-Suchar G, Strupińska M, Jaworski P, Winiecka I, Stables JP: Synthesis and anticonvulsant activity of some amino acid derivatives. Part 2: Derivatives of Gly, Ala, Leu, Pro, Trp, Phe(4 Cl), Ala(alpha-Me). Pharmazie, 1996, 51, 212-215.
8. Paruszewski R, Strupińska M, Stables JP, Śwhiader M, Czuczwar S, Kleinrok Z, Turski W: Amino acid derivatives with anticonvulsant activity. Chem Pharm. Bull (Tokyo), 2001, 49, 629-631.
9. Światder M, Kuźniar H, Kleinrok Z, Czuczwar SJ: Influence of LY 300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice. Pol J Pharmacol, 2003, 55, 103-107.
10. Świader MJ, Luszczki JJ, Pilip S, Kozicka M, Parada-Turska J, Czuczwar SJ: Omeprazole affects neither electroconvulsive threshold nor anticonvulsant activity of diphenylhydantoin and carbamazepine in mice. Pharmacol Rep, 2005, 57, 536-539.
11. Turski L, Meldrum BS, Turski WA, Watkins JC: Evidence that antagonism at non-NMDA receptors results in anticonvulsant action. Eur J Pharmacol, 1987, 136, 69-73.